AstraZeneca is strengthening its bacterial vaccine pipeline through the acquisition of US biotechnology company Omniose.
HHS has introduced an interim peptide compounding policy covering six substances, creating new opportunities and raising pharmaceutical safety concerns.
The Bulk Drug PLI Scheme is set for a proposed Rs 7,000 crore revamp to address India's pharmaceutical manufacturing challenges.
CDMO growth is becoming a central focus for BDR Pharma as it expands its pharmaceutical manufacturing capabilities and international business opportunities.
Alembic Pharmaceuticals' USFDA approval strengthens its position in the generic eye drops market through a specialised ophthalmic formulation.
Eye risks associated with GLP-1 medicines are drawing greater attention as millions of patients use these drugs for diabetes and weight management.
Stroke prevention remains a major challenge even after patients survive an initial ischemic stroke or a high-risk transient ischemic attack (TIA).
TB deaths remain a serious challenge when patients arrive already severely ill, and many lose their lives soon after diagnosis. Tamil Nadu now shows clear progress by cutting TB deaths by at least 38 percent through its statewide care initiative.
Cancer drug price cuts are expected to save patients Rs 3,540 crore annually, improving affordability through revised medicine prices.
Morepen expands its US pharma business beyond API manufacturing with its first prescription generic launch, strengthening its presence in the US market.
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")
